Abstract
Today, interruption of the renin—angiotensin system with angiotensin-converting enzyme (ACE) inhibitors represents a well-accepted therapeutic approach to control high blood pressure and to treat patients with congestive heart failure. After more than 10 years of a wide clinical use, ACE inhibitors have not only turned out to be effective in reducing blood pressure of hypertensive patients and in improving survival of patients with congestive failure, they have also produced some interesting metabolic effects, such as raising potassium levels and restoring normal insulin sensitivity. In addition, they can alter the distribution of cardiac output, resulting in marked changes in cardiac, cerebral, and renal tissue perfusion with potential long-term beneficial effects that may go beyond those expected through the reduction of blood pressure. Thus, blood pressure reduction with ACE inhibitors has been shown to provide cardiac protection following myocardial infarction as well as renal protection in patients with diabetic or nondiabetic chronic renal failure. These favorable metabolic and tissue-protecting effects of ACE inhibitors have enlarged considerably their clinical applications.1
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Waeber B, Nussberger J, Brunner HR: Angiotensin-converting enzyme inhibitors in hypertension. In Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1990, pp. 2209–2232.
Timmermans PBMWM, Carini DJ, Chin AT, et al: The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 4:275S–281S, 1991.
Christen Y, Waeber B, Nussberger J, et al: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 83:1333–1342, 1991.
Wong PC, Price WA, Chiu AT, et al: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihyperten sive agent. J Pharmacol Exp Ther 255:211–217, 1990.
Munafo H, Christen Y, Nussberger J, et al: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 51(5):513–521, 1992.
Ohtawa M, Takayama F, Saithoh K, et al: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 35 (3):290–297, 1993.
Goldberg MR, Tanaka W, Barchowsky A, et al: Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 21:704–713, 1993.
Doig JK, MacFayden RJ, Sweet CS, et al: Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MD954), in salt-deplete normal man. J Cardiovasc Pharmacol 21(5):732–738, 1993.
Burnier M, Rutschmann B, Nussberger J, et al: Salt dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339–347, 1993.
Martinez F, Schmitt F, Natov S, et al: Renal effects of losartan and enalapril alone and in combination in healthy volunteers. In Eliahou HE, Iaina A, Bar-Khazim Y (eds): Proceedings of the International Society of Nephrology. Jerusalem, 1993, p. 228.
Nakashima M, Uematsu T, Kosuge K, et al: Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42:333–335, 1992.
Nelson E, Arcuri K, Ikeda L, et al: Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 5:19A, 1992.
Weber MA: Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens 5:247S–251S, 1992.
Tsunoda K, Abe K, Hagino T, et al: Hypotensive effect of losartan a nonpeptide angiotensin II receptor antagonist in essential hypertension. Am J Hypertens 6(1):28–32, 1993.
Sweet CS, Bradstreet D, Nelson EB, et al: Pharmacodynamic activity of intravenous E-3174,the metabolite of losartan in hypertensive patients. Am J Hypertens 6(5):93A, 1993.
Lafayette RA, Mayer G, Park SK, et al: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766–771, 1992.
Shaw W, Keane W, Sica D, et al: Safety and antihypertensive effects of losartan MK-954 or DuP 753 a new angiotensin II receptor antagonist in patients with hypertension and renal disease. Clin Pharmacol Ther 53(2): 140, 1993.
Gansevoort T, de Zeeuw D, de Jong P: Similar systemic and renal effects of angiotensin-II (A-II) receptor antagonism and ACE inhibition (ACEi) in non-diabetic renal disease. Kidney Int 43:967, 1993.
Lo MW, Shahinfar S, Furtek CI, et al: Pharmacokinetics of losartan MK-954 or DuP 753 in patients with renal insufficiency. Clin Pharmacol Ther 53(2): 160, 1993.
Gottlieb SS, Dickstein K, Fleck E, et al: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 86(4 suppl 1):I120, 1992.
Lacourciere Y, Snavely DB, Faison EP, et al: Effects of modulators of the renin angiotensin system in cough. Abstract book of the satellite symposium to the Sixth European Meeting on Hypertension, “Angiotensin II antagonism: A new advance in the treatment of hypertension,” Milan 1993, pp. 22–23.
Cannon PJ, Stason WB, Demartini FE, et al: Hyperuricemia in primary and renal hypertension. N Engl J Med 275:457–464, 1966.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Burnier, M., Waeber, B., Brunner, H.R. (1994). Clinical Application of Treatment with Angiotensin Receptor Antagonists. In: Saavedra, J.M., Timmermans, P.B.M.W.M. (eds) Angiotensin Receptors. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2464-9_20
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2464-9_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6049-0
Online ISBN: 978-1-4615-2464-9
eBook Packages: Springer Book Archive